MediWound Ltd. Stock News

MediWound Ltd. (NASDAQ:MDWD ) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President, Strategy & Corporate Development Conference Call Participants Josh Jennings - Cowen Swayampakula Ramakanth - H.C.

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cas h Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, Nove...

MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling...

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch -...

Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference C all T oday, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug...

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients